An update on LDL apheresis for nephrotic syndrome (2024)

Table of Contents
List of references Publications that cite this publication FAQs

An update on LDL apheresis for nephrotic syndrome (1) https://doi.org/10.1007/s00467-018-4061-9 · An update on LDL apheresis for nephrotic syndrome (2)

Journal: Pediatric Nephrology, 2018, №10, p.1655-1669

Publisher: Springer Science and Business Media LLC

Authors: Rupesh Raina, Vinod Krishnappa

List of references

  1. Lupien PJ, Moorjani S, Awad J (1976) A new approach to the management of familial hypercholesterolaemia: removal of plasma-cholesterol based on the principle of affinity chromatography. Lancet 1:1261–1265
    An update on LDL apheresis for nephrotic syndrome (3) https://doi.org/10.1016/S0140-6736(76)91736-0
  2. Stoffel W, Borberg H, Greve V (1981) Application of specific extracorporeal removal of low density lipoprotein in familial hypercholesterolaemia. Lancet 2:1005–1007
    An update on LDL apheresis for nephrotic syndrome (4) https://doi.org/10.1016/S0140-6736(81)91213-7
  3. Thompson GR (2003) LDL apheresis. Atherosclerosis 167:1–13
    An update on LDL apheresis for nephrotic syndrome (5) https://doi.org/10.1016/S0021-9150(02)00251-4
  4. Kobayashi S (2008) Applications of LDL-apheresis in nephrology. Clin Exp Nephrol 12:9–15
    An update on LDL apheresis for nephrotic syndrome (6) https://doi.org/10.1007/s10157-007-0003-8
  5. Agrawal S, Zaritsky JJ, Fornoni A, Smoyer WE (2018) Dyslipidaemia in nephrotic syndrome: mechanisms and treatment. Nat Rev Nephrol 14:57–70
    An update on LDL apheresis for nephrotic syndrome (7) https://doi.org/10.1038/nrneph.2017.155
  6. Julius U (2018) Current role of lipoprotein apheresis in the treatment of high-risk patients. J Cardiovasc Dev Dis. https://doi.org/10.3390/jcdd5020027
    An update on LDL apheresis for nephrotic syndrome (8) https://doi.org/10.3390/jcdd5020027
  7. Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Yuzawa Y, Takemura T, Sugiyama S, Nishizawa Y, Ogahara S, Yorioka N, Sakai S, Ogura Y, Yukawa S, Iino Y, Imai E, Matsuo S, Saito T (2015) Immediate therapeutic efficacy of low-density lipoprotein apheresis for drug-resistant nephrotic syndrome: evidence from the short-term results from the POLARIS Study. Clin Exp Nephrol 19:379–386
    An update on LDL apheresis for nephrotic syndrome (9) https://doi.org/10.1007/s10157-014-0996-8
  8. Moorhead JF, Chan MK, El-Nahas M, Varghese Z (1982) Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease. Lancet 2:1309–1311
    An update on LDL apheresis for nephrotic syndrome (10) https://doi.org/10.1016/S0140-6736(82)91513-6
  9. Kasiske BL, O'Donnell MP, Cleary MP, Keane WF (1988) Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int 33:667–672
    An update on LDL apheresis for nephrotic syndrome (11) https://doi.org/10.1038/ki.1988.51
  10. Ota T, Takamura T, Ando H, Nohara E, Yamash*ta H, Kobayashi K (2003) Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 46:843–851
    An update on LDL apheresis for nephrotic syndrome (12) https://doi.org/10.1007/s00125-003-1099-3
  11. Li C, Lim SW, Choi BS, Lee SH, Cha JH, Kim IS, Kim J, Yang CW (2005) Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy. Am J Nephrol 25:611–620
    An update on LDL apheresis for nephrotic syndrome (13) https://doi.org/10.1159/000089905
  12. Shibata S, Nagase M, Fujita T (2006) Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling. J Am Soc Nephrol 17:754–764
    An update on LDL apheresis for nephrotic syndrome (14) https://doi.org/10.1681/ASN.2005050571
  13. Cormack-Aboud FC, Brinkkoetter PT, Pippin JW, Shankland SJ, Durvasula RV (2009) Rosuvastatin protects against podocyte apoptosis in vitro. Nephrol Dial Transplant 24:404–412
    An update on LDL apheresis for nephrotic syndrome (15) https://doi.org/10.1093/ndt/gfn528
  14. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, Koide H (2002) Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 17:798–802
    An update on LDL apheresis for nephrotic syndrome (16) https://doi.org/10.1093/ndt/17.5.798
  15. Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AN, Bouloukos VI, Elisaf M (2004) The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 57:728–734
    An update on LDL apheresis for nephrotic syndrome (17) https://doi.org/10.1136/jcp.2003.012989
  16. Sandhu S, Wiebe N, Fried LF, Tonelli M (2006) Statins for improving renal outcomes: a meta-analysis. J Am Soc Nephrol 17:2006–2016
    An update on LDL apheresis for nephrotic syndrome (18) https://doi.org/10.1681/ASN.2006010012
  17. Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L (2013) Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev:Cd005425. https://doi.org/10.1002/14651858.CD005425.pub
    An update on LDL apheresis for nephrotic syndrome (19) https://doi.org/10.1002/14651858.CD005425.pub
  18. Muso E (2014) Beneficial effect of LDL-apheresis in refractory nephrotic syndrome. Clin Exp Nephrol 18:286–290
    An update on LDL apheresis for nephrotic syndrome (20) https://doi.org/10.1007/s10157-013-0930-5
  19. Tojo K, Sakai S, Miyahara T (1988) Possible therapeutic application of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Nihon Jinzo Gakkai shi 30:1153–1160
  20. Hattori M, Chikamoto H, Akioka Y, Nakakura H, Ogino D, Matsunaga A, f*ckazawa A, Miyakawa S, Khono M, Kawaguchi H, Ito K (2003) A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 42:1121–1130
    An update on LDL apheresis for nephrotic syndrome (21) https://doi.org/10.1053/j.ajkd.2003.08.012
  21. Yokoyama K, Sakai S, Sigematsu T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T (1998) LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. Clin Nephrol 50:1–7
  22. Muso E, Yashiro M, Matsushima M, Yoshida H, Sawanishi K, Sasayama S (1994) Does LDL-apheresis in steroid-resistant nephrotic syndrome affect prognosis? Nephrol Dial T ransplant 9:257–264
  23. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Takemura T, Miki S, Kuwahara T, Takamitsu Y, Tsubakihara Y (2001) Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 89:408–415
    An update on LDL apheresis for nephrotic syndrome (22) https://doi.org/10.1159/000046112
  24. Muso E, Mune M, Fujii Y, Imai E, Ueda N, Hatta K, Imada A, Miki S, Kuwahara T, Takamitsu Y, Takemura T, Tsubakihara Y (1999) Low density lipoprotein apheresis therapy for steroid-resistant nephrotic syndrome. Kansai-FGS-Apheresis Treatment (K-FLAT) Study Group. Kidney Int Suppl 71:S122–S125
    An update on LDL apheresis for nephrotic syndrome (23) https://doi.org/10.1046/j.1523-1755.1999.07130.x
  25. Muso E, Mune M, Yorioka N, Nishizawa Y, Hirano T, Hattori M, Sugiyama S, Watanabe T, Kimura K, Yokoyama H, Sato H, Saito T (2007) Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol 67:341–344
    An update on LDL apheresis for nephrotic syndrome (24) https://doi.org/10.5414/CNP67341
  26. Bobulescu IA (2010) Renal lipid metabolism and lipotoxicity. Curr Opin Nephrol Hypertens 19:393–402
    An update on LDL apheresis for nephrotic syndrome (25) https://doi.org/10.1097/MNH.0b013e32833aa4ac
  27. Ruan XZ, Varghese Z, Moorhead JF (2009) An update on the lipid nephrotoxicity hypothesis. Nat Rev Nephrol 5:713–721
    An update on LDL apheresis for nephrotic syndrome (26) https://doi.org/10.1038/nrneph.2009.184
  28. Balson KR, Niall JF, Best JD (1996) Glomerular lipid deposition and proteinuria in a patient with familial dysbetalipoproteinaemia. J Intern Med 240:157–159
    An update on LDL apheresis for nephrotic syndrome (27) https://doi.org/10.1046/j.1365-2796.1996.501855000.x
  29. Jennette JC, Falk RJ (1990) Adult minimal change glomerulopathy with acute renal failure. Am J Kidney Dis 16:432–437
    An update on LDL apheresis for nephrotic syndrome (28) https://doi.org/10.1016/S0272-6386(12)80055-2
  30. Magil AB, Cohen AH (1989) Monocytes and focal glomerulosclerosis. LabInvest 61:404–409
  31. Hovig T, Blomhoff JP, Holme R, Flatmark A, Gjone E (1978) Plasma lipoprotein alterations and morphologic changes with lipid deposition in the kidney of patients with hepatorenal syndrome. Lab Investig 38:540–549
  32. Gubler MC, Lenoir G, Grunfeld JP, Ulmann A, Droz D, Habib R (1978) Early renal changes in hemizygous and heterozygous patients with Fabry’s disease. Kidney Int 13:223–235
    An update on LDL apheresis for nephrotic syndrome (29) https://doi.org/10.1038/ki.1978.32
  33. Druilhet RE, Overturf ML, Kirkendall WM (1978) Cortical and medullary lipids of normal and nephrosclerotic human kidney. Int J BioChemiPhysics 9:729–734
    An update on LDL apheresis for nephrotic syndrome (30) https://doi.org/10.1016/0020-711X(78)90040-X
  34. Sam R, Wu H, Yue L, Mazzone T, Schwartz MM, Arruda JA, Dunea G, Singh AK (2006) Lipoprotein glomerulopathy: a new apolipoprotein E mutation with enhanced glomerular binding. Am J Kidney Dis 47:539–548
    An update on LDL apheresis for nephrotic syndrome (31) https://doi.org/10.1053/j.ajkd.2005.12.031
  35. Johnson AC, Stahl A, Zager RA (2005) Triglyceride accumulation in injured renal tubular cells: alterations in both synthetic and catabolic pathways. Kidney Int 67:2196–2209
    An update on LDL apheresis for nephrotic syndrome (32) https://doi.org/10.1111/j.1523-1755.2005.00325.x
  36. Listenberger LL, Han X, Lewis SE, Cases S, Farese RV Jr, Ory DS, Schaffer JE (2003) Triglyceride accumulation protects against fatty acid-induced lipotoxicity. Proc Natl Acad Sci U S A 100:3077–3082
    An update on LDL apheresis for nephrotic syndrome (33) https://doi.org/10.1073/pnas.0630588100
  37. Koyama K, Chen G, Lee Y, Unger RH (1997) Tissue triglycerides, insulin resistance, and insulin production: implications for hyperinsulinemia of obesity. Am J Phys 273:E708–E713
  38. Feldkamp T, Weinberg JM, Horbelt M, Von Kropff C, Witzke O, Nurnberger J, Kribben A (2009) Evidence for involvement of nonesterified fatty acid-induced protonophoric uncoupling during mitochondrial dysfunction caused by hypoxia and reoxygenation. Nephrol Dial Transplant 24:43–51
    An update on LDL apheresis for nephrotic syndrome (34) https://doi.org/10.1093/ndt/gfn436
  39. Weinberg JM (2006) Lipotoxicity. Kidney Int 70:1560–1566
    An update on LDL apheresis for nephrotic syndrome (35) https://doi.org/10.1038/sj.ki.5001834
  40. Feldkamp T, Kribben A, Roeser NF, Senter RA, Weinberg JM (2006) Accumulation of nonesterified fatty acids causes the sustained energetic deficit in kidney proximal tubules after hypoxia-reoxygenation. Am J Phys Renal Phys 290:F465–F477
  41. Schaffer JE (2003) Lipotoxicity: when tissues overeat. Curr Opin Lipidol 14:281–287
    An update on LDL apheresis for nephrotic syndrome (36) https://doi.org/10.1097/00041433-200306000-00008
  42. Axelsson J, Bergsten A, Qureshi AR, Heimburger O, Barany P, Lonnqvist F, Lindholm B, Nordfors L, Alvestrand A, Stenvinkel P (2006) Elevated resistin levels in chronic kidney disease are associated with decreased glomerular filtration rate and inflammation, but not with insulin resistance. Kidney Int 69:596–604
    An update on LDL apheresis for nephrotic syndrome (37) https://doi.org/10.1038/sj.ki.5000089
  43. Mitsnefes M, Kartal J, Khoury P, Daniels S (2007) Adiponectin in children with chronic kidney disease: role of adiposity and kidney dysfunction. Clin J Am Soc Nephrol 2:46–50
    An update on LDL apheresis for nephrotic syndrome (38) https://doi.org/10.2215/CJN.02790806
  44. Capettini LS, Montecucco F, Mach F, Stergiopulos N, Santos RA, da Silva RF (2012) Role of renin-angiotensin system in inflammation, immunity and aging. Curr Pharm Des 18:963–970
    An update on LDL apheresis for nephrotic syndrome (39) https://doi.org/10.2174/138161212799436593
  45. Bussolati B, Deregibus MC, Fonsato V, Doublier S, Spatola T, Procida S, Di Carlo F, Camussi G (2005) Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 16:1936–1947
    An update on LDL apheresis for nephrotic syndrome (40) https://doi.org/10.1681/ASN.2004080629
  46. Chung JJ, Huber TB, Godel M, Jarad G, Hartleben B, Kwoh C, Keil A, Karpitskiy A, Hu J, Huh CJ, Cella M, Gross RW, Miner JH, Shaw AS (2015) Albumin-associated free fatty acids induce macropinocytosis in podocytes. J Clin Invest 125:2307–2316
    An update on LDL apheresis for nephrotic syndrome (41) https://doi.org/10.1172/JCI79641
  47. Okamura K, Dummer P, Kopp J, Qiu L, Levi M, Faubel S, Blaine J (2013) Endocytosis of albumin by podocytes elicits an inflammatory response and induces apoptotic cell death. PLoS One 8:e54817
    An update on LDL apheresis for nephrotic syndrome (42) https://doi.org/10.1371/journal.pone.0054817
  48. Yoshikawa N, Ito H, Akamatsu R, Hazikano H, Okada S, Matsuo T (1986) Glomerular podocyte vacuolation in focal segmental glomerulosclerosis. Arch Pathol Lab Med 110:394–398
  49. Jovin IS, Taborski U, Muller-Berghaus G (2000) Analysis of the long-term efficacy and selectivity of immunoadsorption columns for low density lipoprotein apheresis. ASAIO J 46:298–300
    An update on LDL apheresis for nephrotic syndrome (43) https://doi.org/10.1097/00002480-200005000-00011
  50. Gordon BR, Kelsey SF, Bilheimer DW, Brown DC, Dau PC, Gotto AM Jr, Illingworth DR, Jones PH, Leitman SF, Prihoda JS et al (1992) Treatment of refractory familial hypercholesterolemia by low-density lipoprotein apheresis using an automated dextran sulfate cellulose adsorption system. The Liposorber Study Group. Am J Cardiol 70:1010–1016
    An update on LDL apheresis for nephrotic syndrome (44) https://doi.org/10.1016/0002-9149(92)90352-Y
  51. Armstrong VW, Schuff-Werner P, Eisenhauer T, Helmhold M, Stix M, Seidel D (1994) Heparin extracorporeal LDL precipitation (HELP): an effective apheresis procedure for lowering Lp (a) levels. Chem Phys Lipids 67-68:315–321
    An update on LDL apheresis for nephrotic syndrome (45) https://doi.org/10.1016/0009-3084(94)90152-X
  52. Eisenhauer T, Armstrong VW, Wieland H, Fuchs C, Scheler F, Seidel D (1987) Selective removal of low density lipoproteins (LDL) by precipitation at low pH: first clinical application of the HELP system. Klin Wochenschr 65:161–168
    An update on LDL apheresis for nephrotic syndrome (46) https://doi.org/10.1007/BF01728226
  53. Schettler V, Monazahian M, Wieland E, Ramadori G, Grunewald RW, Thomssen R, Muller GA (2001) Reduction of hepatitis C virus load by H.E.L.P.-LDL apheresis. Eur J Clin Investig 31:154–155
    An update on LDL apheresis for nephrotic syndrome (47) https://doi.org/10.1046/j.1365-2362.2001.00758.x
  54. Moriarty PM, Gibson CA, Shih J, Matias MS (2001) C-reactive protein and other markers of inflammation among patients undergoing HELP LDL apheresis. Atherosclerosis 158:495–498
    An update on LDL apheresis for nephrotic syndrome (48) https://doi.org/10.1016/S0021-9150(01)00633-5
  55. Bosch T, Lennertz A, Kordes B, Samtleben W (1999) Low density lipoprotein hemoperfusion by direct adsorption of lipoproteins from whole blood (DALI apheresis): clinical experience from a single center. Ther Apher 3:209–213
    An update on LDL apheresis for nephrotic syndrome (49) https://doi.org/10.1046/j.1526-0968.1999.00162.x
  56. Bosch T, Schmidt B, Kleophas W, Otto V, Samtleben W (1997) LDL hemoperfusion—a new procedure for LDL apheresis: biocompatibility results from a first pilot study in hypercholesterolemic atherosclerosis patients. Artif Organs 21:1060–1065
    An update on LDL apheresis for nephrotic syndrome (50) https://doi.org/10.1111/j.1525-1594.1997.tb00443.x
  57. Oto J, Suga K, Matsuura S, Kondo S, Ohnishi Y, Inui D, Imanaka H, Kagami S, Nishimura M (2009) Low-density lipoprotein apheresis in a pediatric patient with refractory nephrotic syndrome due to focal segmental glomerulosclerosis. J Anesth 23:284–287
    An update on LDL apheresis for nephrotic syndrome (51) https://doi.org/10.1007/s00540-008-0726-z
  58. Kawasaki Y, Suzuki S, Matsumoto A, Takano K, Suyama K, Hashimoto K, Suzuki J, Suzuki H, Hosoya M (2007) Long-term efficacy of low-density lipoprotein apheresis for focal and segmental glomerulosclerosis. Pediatr Nephrol 22:889–892
    An update on LDL apheresis for nephrotic syndrome (52) https://doi.org/10.1007/s00467-006-0426-6
  59. Hattori M, Ito K, Kawaguchi H, Tanaka T, Kubota R, Khono M (1993) Treatment with a combination of low-density lipoprotein aphaeresis and pravastatin of a patient with drug-resistant nephrotic syndrome due to focal segmental glomerulosclerosis. Pediatr Nephrol 7:196–198
    An update on LDL apheresis for nephrotic syndrome (53) https://doi.org/10.1007/BF00864397
  60. Munoz M, Lumbreras J, Madrid A, Lara LE, Chocron S, Vilalta R, Ariceta G (2017) Complete remission of post-transplant recurrence of focal segmental glomerulosclerosis in children with the use of LDL-apheresis therapy: case report. Pediatric Transplantation. Wiley, Hoboken, p 63
  61. Ito S, Machida H, Inaba A, Harada T, Okuyama K, Nakamura T, Aihara Y, Yokota S (2007) Amelioration of steroids and cyclosporine-resistant nephrotic syndrome by pravastatin. Pediatr Nephrol 22:603–606
    An update on LDL apheresis for nephrotic syndrome (54) https://doi.org/10.1007/s00467-006-0371-4
  62. Tojo K, Sakai S, Miyahara T (1990) Therapeutic trial of low density lipoprotein apheresis (LDL-A) in conjunction with double filtration plasmapheresis (DFPP) in drug-resistant nephrotic syndrome due to focal glomerular sclerosis (FGS). Prog Clin Biol Res 337:193–194
  63. Ishikura K, Matsumoto S, Sako M, Tsuruga K, Nakanishi K, Kamei K, Saito H, Fujinaga S, Hamasaki Y, Chikamoto H, Ohtsuka Y, Komatsu Y, Ohta T, Nagai T, Kaito H, Kondo S, Ikezumi Y, Tanaka S, Kaku Y, Iijima K, Japanese Society for Pediatric N (2015) Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. Clin Exp Nephrol 19:6–33
    An update on LDL apheresis for nephrotic syndrome (55) https://doi.org/10.1007/s10157-014-1030-x
  64. FDA (2018) Liposorber® LA-15 System FDA Executive Summary. Available from https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM601669.pdf . Accessed 20 April 2018
  65. Sato Y, Tsunoda S, Nozue T, Pan Q, Wakasugi H, Yoshimura A (2012) Low-density lipoprotein apheresis therapy for steroid- and cyclosporine-resistant idiopathic membranous nephropathy. Intern Med 51:2597–2602
    An update on LDL apheresis for nephrotic syndrome (56) https://doi.org/10.2169/internalmedicine.51.7204
  66. Kobayashi T, Ando Y, Umino T, Miyata Y, Muto S, Hironaka M, Asano Y, Kusano E (2006) Complete remission of minimal-change nephrotic syndrome induced by apheresis monotherapy. Clin Nephrol 65:423–426
    An update on LDL apheresis for nephrotic syndrome (57) https://doi.org/10.5414/CNP65423
  67. Iwahori T, Yoshida M (2000) Low-density lipoprotein apheresis can improve type AA systemic amyloidosis. Nephron 86:248–250
    An update on LDL apheresis for nephrotic syndrome (58) https://doi.org/10.1159/000045774
  68. Shibata T, Okabe E, Sumie A, Ishii T, Tomo T, Yasumori R, Nasu M, Nomura Y (1994) A case of nephrotic syndrome due to IgA nephropathy complicated by acute renal failure and ameriolated by low density lipoprotein (LDL) apheresis. Nihon Toseki Igakkai Zasshi 27:233–236
    An update on LDL apheresis for nephrotic syndrome (59) https://doi.org/10.4009/jsdt.27.233
  69. Daimon S, Saga T, Nakayama M, Nomura Y, Chikaki H, Dan K, Koni I (2000) Dextran sulphate cellulose columns for the treatment of nephrotic syndrome due to inactive lupus nephritis. Nephrol Dial Transplant 15:235–238
    An update on LDL apheresis for nephrotic syndrome (60) https://doi.org/10.1093/ndt/15.2.235
  70. Shiraishi N, Kitamura K, Hayata M, Ogata T, Tajiri-Okamura K, Nakayama Y, Kohda Y, Tomita K, Mukoyama M (2015) Low-density lipoprotein apheresis for proteinuria in lupus nephritis with intraglomerular foam cells containing cholesterol crystals. Am J Kidney Dis 65:490–493
    An update on LDL apheresis for nephrotic syndrome (61) https://doi.org/10.1053/j.ajkd.2014.09.028
  71. Ruf RG, Lichtenberger A, Karle SM, Haas JP, Anacleto FE, Schultheiss M, Zalewski I, Imm A, Ruf EM, Mucha B, Bagga A, Neuhaus T, Fuchshuber A, Bakkaloglu A, Hildebrandt F (2004) Patients with mutations in NPHS2 (podocin) do not respond to standard steroid treatment of nephrotic syndrome. J Am Soc Nephrol 15:722–732
    An update on LDL apheresis for nephrotic syndrome (62) https://doi.org/10.1097/01.ASN.0000113552.59155.72
  72. Muso E, Mune M, Hirano T, Hattori M, Kimura K, Watanabe T, Yokoyama H, Sato H, Uchida S, Wada T, Shoji T, Takemura T, Yuzawa Y, Ogahara S, Sugiyama S, Iino Y, Sakai S, Ogura Y, Yukawa S, Nishizawa Y, Yorioka N, Imai E, Matsuo S, Saito T (2015) A prospective observational survey on the long-term effect of LDL apheresis on drug-resistant nephrotic syndrome. Nephron Extra 5:58–66
    An update on LDL apheresis for nephrotic syndrome (63) https://doi.org/10.1159/000437338
  73. Tanaka A, Nakamura T, Sato E, Node K (2016) Impact of low-density lipoprotein apheresis for nephrotic syndrome in a patient with immunoglobulin M nephropathy. Nephrology 21:1073–1074
    An update on LDL apheresis for nephrotic syndrome (64) https://doi.org/10.1111/nep.12711
  74. Stenvinkel P, Alvestrand A, Angelin B, Eriksson M (2000) LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Eur J Clin Investig 30:866–870
    An update on LDL apheresis for nephrotic syndrome (65) https://doi.org/10.1046/j.1365-2362.2000.00716.x
  75. Brunton C, Varghese Z, Moorhead JF (1999) Lipopheresis in the nephrotic syndrome. Kidney Int Suppl 71:S6–S9
    An update on LDL apheresis for nephrotic syndrome (66) https://doi.org/10.1046/j.1523-1755.1999.07102.x
  76. Okada T, Takahashi H, Ogura M, Nakao T, Shimizu T (1996) Complete remission of steroid-resistant minimal-change nephrotic syndrome by cyclosporin after additional low-density lipoprotein apheresis treatment. Nihon Jinzo Gakkai shi 38:46–51
  77. FDA (2018) FDA Listing of CDRH Humanitarian Device Exemptions. Available from https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfhde/hde.cfm?id=H170002 . Accessed 20 April 2018
  78. Sannomiya A, Murakami T, Koyama I, Nitta K, Nakajima I, Fuchinoue S (2018) Preoperative low-density lipoprotein apheresis for preventing recurrence of focal segmental glomerulosclerosis after kidney transplantation. J Transp Secur 2018:1–5
  79. FDA (2013) A patient guide to the Liposorber LA-15 System. Available from https://www.accessdata.fda.gov/cdrh_docs/pdf12/H120005D.pdf . Accessed 20 April 2018
  80. Blue Cross Blue Shield of North Carolina (2013) Blue Cross Blue Shield of North Carolina Corporate Medical Policy: lipid apheresis. Available from https://www.bluecrossnc.com/sites/default/files/document/attachment/services/public/pdfs/medicalpolicy/lipid_apheresis.pdf . Accessed 23 April 2018.
  81. NIH (2014) Post approval study of Liposorber LA-15 System for the treatment of focal segmental glomerulosclerosis in children. Available from https://clinicaltrials.gov/ct2/show/NCT02235857 . April 28 2018
  82. FDA (2013) LIPOSORBER LA-15 SYSTEM operator’s manual. Available from www.accessdata.fda.gov/cdrh_docs/pdf12/H120005C.pdf April 26 2018

Publications that cite this publication

Treatment of post-transplant recurrent FSGS in children using plasmapheresis and augmentation of immunosuppression

Jaime M. Restrepo, Laura Torres-Canchala, Hernando Londoño, Eliana Manzi, Michael J. G. Somers

An update on LDL apheresis for nephrotic syndrome (67) https://doi.org/10.1186/s12882-022-02768-w · An update on LDL apheresis for nephrotic syndrome (68)

2022, BMC Nephrology, №1

Scopus

WoS

Crossref citations:0

Beneficial effects of procyanidin B2 on adriamycin-induced nephrotic syndrome mice: the multi-action mechanism for ameliorating glomerular permselectivity injury

Chuanping Zhao, Jiamei Tang, Xiaoya Li, Zihan Yan, Liangliang Zhao, Wenbo Lang, Chunmao Yuan, Chengyan Zhou

An update on LDL apheresis for nephrotic syndrome (69) https://doi.org/10.1039/d1fo03616e · An update on LDL apheresis for nephrotic syndrome (70)

Low-density Lipoprotein Receptor Activities, Lipids, Apolipoprotein, and Clinical Course of Patients with Steroid-resistant Nephrotic Syndrome Treated with Low-density Lipoprotein Apheresis: A Case Series

Hisato Shima, Yusuke Higashiguchi, Toshio Doi, Megumi Harada, Takuya Okamoto, Tomoko Inoue, Manabu Tashiro, Kazuyoshi Okada, Jun Minakuchi

An update on LDL apheresis for nephrotic syndrome (71) https://doi.org/10.2169/internalmedicine.1922-23

2024, Internal Medicine, №3, p.433-438

Scopus

WoS

Crossref citations:0

Unveiling Nephrotic Syndrome: Causes, Pathogenesis, and Treatment

Akramov Abdullokh Ahmad o‘g‘li, Khamdamov Botirjon Nusratullo oʼgʼli, Haydarov Og'abek Ulug'bek o'g'li, Murtozoyeva Ug'iloy Saydulla qizi, Qodirov Javohir Jasurbek o‘g‘li, G'aybullayev Kamronbek Faxriddin o'g'li

An update on LDL apheresis for nephrotic syndrome (72) https://doi.org/10.51699/ijcm.v4i1.617

2024, International Journal of Culture and Modernity, №1, p.1-3

Crossref citations:0

Advances in Apheresis Techniques and Therapies in the Pediatric Setting

Gordon Hong, Evelyn Lee, Keval Yerigeri, Sidharth Sethi, Felipe Cavagnaro, Rupesh Raina

An update on LDL apheresis for nephrotic syndrome (73) https://doi.org/10.1007/s40124-022-00275-y

2022, Current Pediatrics Reports, №4, p.214-226

WoS

Crossref citations:0

Nongenetic Forms of Steroid-Resistant Nephrotic Syndrome

Markus Josef Kemper, Keisha Gibson, Aditi Sinha

An update on LDL apheresis for nephrotic syndrome (74) https://doi.org/10.1007/978-3-030-52719-8_93

2022, Pediatric Nephrology, p.387-410

Crossref citations:0

Comprehensive analysis of microRNA expression and target prediction in children with Nephrotic syndrome

Pricilla Charmine, Vettriselvi Venkatesan, Sangeetha Geminiganesan, Bollam Rangaswamy Nammalwar, Sudha Ekambaram, C.D.Mohana Priya

An update on LDL apheresis for nephrotic syndrome (75) https://doi.org/10.21203/rs.3.rs-2201200/v1

2022

Crossref citations:0

LDL-apheresis-induced remission of focal segmental glomerulosclerosis recurrence in pediatric renal transplant recipients

Lokesh Shah, David K. Hooper, Daryl Okamura, Dean Wallace, Divya Moodalbail, Caroline Gluck, Ania Koziell, Joshua J. Zaritsky

An update on LDL apheresis for nephrotic syndrome (76) https://doi.org/10.1007/s00467-019-04296-6 · An update on LDL apheresis for nephrotic syndrome (77)

2019, Pediatric Nephrology, №11, p.2343-2350

Scopus

WoS

Crossref citations:1

IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome

Agnes Trautmann, on behalf of the International Pediatric Nephrology Association, Marina Vivarelli, Susan Samuel, Debbie Gipson, Aditi Sinha, Franz Schaefer, Ng Kar Hui, Olivia Boyer, Moin A Saleem, Luciana Feltran, Janina Müller-Deile, Jan Ulrich Becker, Francisco Cano, Hong Xu, Yam Ngo Lim, William Smoyer, Ifeoma Anochie, Koichi Nakanishi, Elisabeth Hodson, Dieter Haffner

An update on LDL apheresis for nephrotic syndrome (78) https://doi.org/10.1007/s00467-020-04519-1 · An update on LDL apheresis for nephrotic syndrome (79)

2020, Pediatric Nephrology, №8, p.1529-1561

Scopus

WoS

Crossref citations:98

<p>The Supportive Treatment of IgA Nephropathy and Idiopathic Nephrotic Syndrome: How Useful are Omega-3 Polyunsaturated Fatty Acids?</p>

Samuel N Uwaezuoke, Uzoamaka V Muoneke, Ngozi R Mbanefo

An update on LDL apheresis for nephrotic syndrome (80) https://doi.org/10.2147/ijnrd.s237527 · An update on LDL apheresis for nephrotic syndrome (81)

2020, International Journal of Nephrology and Renovascular Disease, p.27-35

Scopus

WoS

Crossref citations:7

Find all citations of the publication

An update on LDL apheresis for nephrotic syndrome (2024)

FAQs

Does LDL apheresis work? ›

One procedure lowers LDL cholesterol by 65% to 70%. Repeated procedures, generally every one to two weeks, are needed to maintain low cholesterol levels for patients with familial hypercholesterolemia.

View More ›
How often should you have LDL apheresis? ›

A typical treatment takes two to four hours and must be repeated every two to three weeks.

Find Out More ›
What is LDL apheresis for FSGS? ›

LDL apheresis removes low-density lipoproteins (LDL), very low-density lipoproteins (VLDLs), lipoprotein(a), and triglycerides (TGs) from the blood while keeping high-density lipoproteins (HDL) and other proteins and antibodies.

Read The Full Story ›
What does LDL apheresis remove from the blood? ›

LDL apheresis removes unwanted LDL cholesterol from the blood. A machine is used to pump the patient's blood through a filter that selectively removes LDL particles containing the cholesterol.

See Details ›
How much does LDL apheresis cost? ›

What is the cost of LDL Apheresis? Most insurance carriers cover the cost of LDL apheresis, which is approximately $2500 per treatment. We will work with you and your insurance carrier to determine your coverage for this procedure.

View More ›
What are the side effects of lipid apheresis? ›

Side effects associated with LDL-apheresis include hypotension (later found to be due to concomitant use of angiotensin-converting enzyme inhibitors), nausea/vomiting, flushing, angina, and fainting. Posttreatment bleeding can occur secondary to heparin used during the procedure.

Discover More ›
Who qualifies for lipoprotein apheresis? ›

In general, apheresis is indicated for patients with hom*ozygous or heterozygous Familial Hypercholesterolemia (FH) and LDL cholesterol levels >300mg/dl, patients with heterozygous FH and high cardiovascular disease risk characteristics with an LDL cholesterol > 200mg/dl, patients with heterozygous FH and cardiovascular ...

Get More Info ›
What is the future of apheresis? ›

Future implications for lipoprotein apheresis will involve vascular diseases that are at present lacking clinically effective therapy, whereas acute and chronic reductions of lipids, vascular inflammation, and/or rheology may improve the clinical outcome.

Find Out More ›
How much does an apheresis machine cost? ›

With equipment priced at $50,000 or more per machine, disposables costing between $1,500 and $3,000 per patient, plus the cost of adding highly trained professionals to oversee the procedures, apheresis is not something that every office practice can afford to or should offer.

Discover More Details ›
What is the new treatment for FSGS? ›

New findings from a team led by the University of Minnesota Medical School show patients with FSGS who were treated with the medication sparsentan experienced improved kidney function—making it a potential new treatment option for the disorder.

Learn More ›

Why is LDL high in nephrotic syndrome? ›

The major lipoproteins, including intermediate density lipoprotein (IDL), very low density lipoprotein (VLDL) and low-density lipoprotein (LDL), and cholesterol are increased in the plasma of patients with nephrotic syndrome, owing mainly to impaired clearance and, to a lesser extent, increased biosynthesis.

Read More ›
What is the best treatment for FSGS? ›

Corticosteroids and immunosuppressive drugs: These medications are used to calm your immune system (your body's defense system) and stop it from attacking your glomeruli. ACE inhibitors and ARBs: These are blood pressure medications used to reduce protein loss and control blood pressure.

Continue Reading ›
What are the side effects of apheresis? ›

As with regular blood donations, apheresis is generally painless. Still, there may be some side effects, such as discomfort in the arm where the needle is inserted, lightheadedness, sweating, or a drop in blood pressure.

Discover More ›
Is LDL apheresis painful? ›

The treatment doesn't hurt, though sometimes it can be hard to find a vein which can make it uncomfortable. There are different types of LDL-apheresis machines and they can work in a few different ways.

Get More Info ›
How long does apheresis last? ›

How long does apheresis take? The treatment takes about 2 to 5 hours, depending on which type of apheresis you get.

Continue Reading ›
What is the best LDL lowering agent? ›

Statins. Statins are one of the better-known types of cholesterol-lowering drugs. Providers choose these for most people because they work well and are considered first-line treatment for most people with elevated cholesterol.

Get More Info Here ›
Can high LDL cholesterol reversed? ›

Completely reversing it isn't possible yet. But taking a statin can reduce the risk of complications from atherosclerosis. The statin fights inflammation, which stabilizes the plaque. For this reason, statins are often key to treating atherosclerosis.

Discover More Details ›
How is LDL removed from blood naturally? ›

Consume more monounsaturated fats

Monounsaturated or “healthy” fats may help to reduce LDL cholesterol. Good sources of monounsaturated fats include : avocados. nuts, such as almonds, peanuts, and Brazil nuts.

Tell Me More ›
Why is red cell apheresis not recommended? ›

Disadvantages are the higher costs of the procedure, the increased use of donor RBC, and the requirement of apheresis devices and trained hospital staff. The most frequent indication for RBC exchange is sickle cell disease (SCD).

Discover More Details ›
Top Articles
How to Make the Best Gluten Free Biscuit Recipe
World's Best Irish Soda Bread Recipe!
Www.patientnotebook/Mmg
Thdgear Promo Code 2023
Tunnel Rush Unblocked Wtf 66 Ez
Quadratic Simultaneous Equations Solver
Lcwc 911 Live Incident List Live Status
The 3 Best Fort Lauderdale Pub Crawls
Rosie Perez Height, Weight, Age, Boyfriend, Family, Facts, Biography
2024 Pride Toronto Raffle – Pride Toronto
Rocky Bfb Asset
Workday and IBM Expand Partnership to Help Customers Plan Return to the Workplace
Latest Posts
Vegan Mapo Tofu: Easy Recipe! - The Woks of Life
Homemade Bread Bowls - Recipe Girl
Article information

Author: Duane Harber

Last Updated:

Views: 5641

Rating: 4 / 5 (71 voted)

Reviews: 94% of readers found this page helpful

Author information

Name: Duane Harber

Birthday: 1999-10-17

Address: Apt. 404 9899 Magnolia Roads, Port Royceville, ID 78186

Phone: +186911129794335

Job: Human Hospitality Planner

Hobby: Listening to music, Orienteering, Knapping, Dance, Mountain biking, Fishing, Pottery

Introduction: My name is Duane Harber, I am a modern, clever, handsome, fair, agreeable, inexpensive, beautiful person who loves writing and wants to share my knowledge and understanding with you.